Isofol Medical AB (OSTO:ISOFOL) ROCE % : -28.25% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Isofol Medical AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Isofol Medical AB's annualized ROCE % for the quarter that ended in Dec. 2023 was -28.25%.

Isofol Medical AB ROCE % Historical Data

The historical data trend for Isofol Medical AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isofol Medical AB ROCE % Chart

Isofol Medical AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-86.62

-214.99

-103.58

-66.90

-26.32

Isofol Medical AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-59.02	-37.85	-21.25	-18.64	-28.25

Isofol Medical AB ROCE % Calculation

Isofol Medical AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-37.071	/	( ( (209.89 - 50.541)	+	(140.597 - 18.253) )	/ 2 )
	=	-37.071	/	( (159.349	+	122.344)	/ 2 )
	=	-37.071	/	140.8465
	=	-26.32 %

Isofol Medical AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-35.816	/	( ( (150.133 - 18.943)	+	(140.597 - 18.253) )	/ 2 )
	=	-35.816	/	( ( 131.19	+	122.344 )	/ 2 )
	=	-35.816	/	126.767
	=	-28.25 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Isofol Medical AB (OSTO:ISOFOL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Isofol Medical AB ROCE % Related Terms

Thank you for viewing the detailed overview of Isofol Medical AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Isofol Medical AB (OSTO:ISOFOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Isofol Medical AB (OSTO:ISOFOL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

5IU:Germany

Address

Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46

Website

http://www.isofol.se

Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.

Isofol Medical AB (OSTO:ISOFOL) Headlines

No Headlines